title: Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy?
abstract: BACKGROUND
  The study was conducted to evaluate whether the detection of serum molecular forms of inhibin (A and B) could be useful for the diagnosis, prognosis and follow-up of placental tumours.
  
  
  METHODS
  A total of 17 patients with hydatidiform mole (n = 13), invasive mole (n = 1) or choriocarcinoma (n = 3) were studied; serum concentrations of inhibins A and B, human chorionic gonadotrophin (HCG) and its free beta subunit (HCGbeta) were measured before chemotherapy (after mole evacuation for eight patients) and also during the course of chemotherapy (for 10 patients).
  
  
  RESULTS
  After evacuation or before chemotherapy for refractory disease, serum inhibin A and B concentrations were found to be increased in 10/17 and 4/17 patients, when HCG and HCGbeta were high in all patients. In 10 patients with a follow-up during treatment, nine had a high concentration of inhibin A which correlated with those of HCG and HCGbeta. Normalization of inhibin A was faster than that of HCG and HCGbeta for three and six patients respectively. There was no correlation between changes of inhibin B and HCGbeta concentrations.
  
  
  CONCLUSIONS
  Our results suggest that inhibins A and B are not useful markers and that HCG determination still remains the most useful marker for diagnosis and follow-up of placental tumours.
authors.affiliation: Medical Department, Gynecological Unit, Institut Gustave-Roussy, 94805 Villejuif, France. pautier@igr.fr
authors.forename: P
authors.initials: P
authors.lastname: Pautier
authors.forename: S
authors.initials: S
authors.lastname: Ghione
authors.forename: S
authors.initials: S
authors.lastname: Brailly-Tabard
authors.forename: C
authors.initials: C
authors.lastname: Lhommé
authors.forename: P
authors.initials: P
authors.lastname: Morice
authors.forename: J M
authors.initials: JM
authors.lastname: Bidart
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002822:Choriocarcinoma / Q000097:blood* / Q000188:drug therapy; D006063:Chorionic Gonadotropin / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000097:blood* / Q000188:drug therapy; D007265:Inhibins / Q000097:blood*; D011247:Pregnancy; D014594:Uterine Neoplasms / Q000097:blood* / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; C422362:inhibin A; C422364:inhibin B; D007265:Inhibins